News : Latest News, Press Releases & Events

Spyryx Biosciences to Present at the 2017 Bio International Convention

DURHAM, N.C., June 16, 2017 – Spyryx Biosciences, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases, today announced that President and Chief Executive Officer, John Taylor, will present a corporate overview at the 2017 BIO International Convention at the San Diego Convention Center in San Diego, California, on Tuesday, June 20 from 3:30 PM–3:45 PM PST/6:30 PM – 6:45PM EDT.

The BIO International Convention allows for public and private companies to provide formal presentations, request face-to-face meetings with biotech investors and executives, attend educational sessions and engage in networking opportunities. For more information, please visit: http://convention.bio.org/about-bio-convention/

About Spyryx Biosciences

Spyryx Biosciences is a privately held, clinical-stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases. Spyryx’s lead clinical candidate, SPX-101, is a novel treatment for cystic fibrosis (CF) that is advancing into Phase 2 in people living with CF. The product has demonstrated a robust ability to restore mucociliary clearance in animal models of the disease and has the potential to improve lung function independent of the disease-causing CFTR mutation. The Spyryx leadership team and scientific staff have extensive experience in the development of respiratory medicines and work closely with a broad group of clinical and scientific experts in the pulmonary field. Spyryx is funded by a first tier syndicate of life science investors, including Canaan Partners, 5AM Ventures and Hatteras Venture Partners. Further information regarding Spyryx Biosciences is available at www.spyryxbio.com.